Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
What antibiotic should I use to treat this patient’s Klebsiella pneumoniae? It’s resistant to carbapenems, and there’s a ...
UNR med students and faculty work to provide free medical services to patients who are uninsured, underinsured or facing ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic ...
In this conversation, Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
Invitation-only working summit convenes FDA, CMS, and industry leaders April 10 in Charlotte, North Carolina. This call ...
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
What does it take to transform an entire health system into a national leader in patient safety? Hartford HealthCare didn’t just ask the question — they answered it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback